Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine.Join our Senior Editors in face-to-face discussions ...
Ep. 76 - FDA Inflection Point: Steve Usdin on Biopharma during Trump 2.0
All presidential transitions with a change of party come with disruption and threats as well as opportunities. But this one, in particular with regard to the implications for FDA, is different from all those Steve Usdin has been covering in his 30-year tenure as Washington editor at BioCentury.In particular, this is an inflection point for the agency that currently serves as the global gold standard for drug regulation, said Usdin on a special edition of The BioCentury Show covering the ramifications for the biopharma industry of the second Trump administration. Usdin has recently outlined the threats and opportunities that the new era presents, and he elaborated further on those in a discussion with Editor in Chief Simone Fishburn.View full story: https://www.biocentury.com/article/654798#biotech #biopharma #pharma #lifescience #politics #policy #fda #ftc #biosecure #ira00:00 - Introduction05:06 - Inflection Point at FDA14:10 - Changes at the FTC16:43 - China, Biosecure21:30 - The IRA
--------
34:01
Ep. 75 - PBMs, IRA, RFK Jr: A Conversation With Rep. Jake Auchincloss
Rep. Jake Auchincloss (D-Mass.), an influential voice in Congress on life sciences issues, gained stature last week when he was appointed to serve on the Energy & Commerce Committee, giving him a seat at the table for debates over legislation affecting FDA, CMS and NIH and a host of issues of critical importance to the biopharma industry.In an interview with Washington Editor Steve Usdin on The BioCentury Show, Auchincloss outlined his priorities for the 119th Congress, from pushing “muscular” PBM reform over the congressional finish line to finding bipartisan support for refining the IRA's orphan drug exemption and advancing methods to evaluate the social value of medicines.View full story: https://www.biocentury.com/article/654659#biotech #biopharma #pharma #lifescience #politics #policy #law 00:00 - Introduction01:08 - New Congress & RFK Jr.10:09 - China & Biotech16:36 - Assessing Drugs’ Value
--------
36:04
Ep. 74 - Chris Bardon on Biotech’s Recovery: Valuations, Obesity Drugs, and M&A
Specialist public investors are doing their best to hold up the sector, but biotech still has to wash out many of the lower quality companies that were funded during the boom and ended up driving the generalists away, said MPM Bioimpact's Chris Bardon on The BioCentury Show. Bardon said the market hasn’t yet found the footing that will see an opening of the IPO window and a swing of positive sentiment. But although markets aren’t yet out of the woods, she said M&A will remain robust for years, fueled by obesity drug revenues.View full story: https://www.biocentury.com/article/654649#biotech #biopharma #pharma #lifescience #financing #investing00:00 - Introduction01:30 - Market Sentiment06:19 - IPO Window12:04 - M&A Outlook19:51 - The Obesity Landscape
--------
34:03
Ep. 73 - Resilience and the CEO’s Paradox: Aoife Brennan on Leading in Biotech
Leading biotech companies through the turbulence of the past few years and the uncertainty of the next ones takes not just resilience, but an ability to grapple with the CEO’s paradox, according to Climb Bio CEO Aoife Brennan. This paradox requires preparing for repeated setbacks while planning optimistically, a duality that has been the story of biotech since the outbreak of the pandemic, said Brennan. In conversation with Editor in Chief Simone Fishburn on The BioCentury Show, Brennan discusses how CEOs are managing through uncertainty, and why "boring" naked mAbs are the smart move in one field.View full story: https://www.biocentury.com/article/654451#biotech #biopharma #pharma #lifescience00:00 - Introduction00:59 - State of Play for Biotech04:34 - How to Choose a CEO Job18:49 - New Era of Discipline26:51 - Building a Team
--------
32:12
Ep. 72 - Outlook for Biotech M&A and Financing: Sidley's Robert Darwin
With new governments both side of the pond, capital markets picking up, and some geopolitical overhang, there’s a mixed feast for biotech, with a net trend to the positive, says Sidley Austin’s Robert Darwin, who specializes in global M&A and private equity for life sciences and healthcare companies and investors. In conversation with Editor in Chief Simone Fishburn on The BioCentury Show, Darwin, who is based in London, discussed the consequences for biotech of the changing forces as we enter 2025: the new Labour government’s recently announced budget, the incoming Trump administration, the improving outlook for the markets, and the ongoing — if not mounting — tensions between the U.S. and China. Across each of these is a considerable amount of uncertainty, but the pluses and minuses add up to net positive outlook, he believes.This episode of The BioCentury Show was sponsored by Cytiva. View full story: https://www.biocentury.com/article/654182#biotech #biopharma #pharma #lifescience #deals00:00 – Introduction01:49 – U.K.’s Place in Global Biotech09:41 – Trump & Biotech17:32 – Deals in 202531:57 – Private Equity in Biotech
Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine.Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues.The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how science is being turned into medicine.Don't miss this event, every two weeks, now available as a video webcast or audio podcast.
UK